Tilos Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $773M

Tilos Therapeutics General Information

Description

Developer of antibody therapeutics designed to treat cancer, fibrosis and related disorders. The company's antibody therapeutics harnesses the power of the immune system to develop new therapies that target key immunological pathways with a primary focus on regulatory T cells and regulation of effector cells, enabling patients to start treatment more quickly, resulting in a better medical outcome.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Corporate Office
  • 65 Hayden Avenue
  • Lexington, MA 02421
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tilos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Jun-2019 $773M 00.00 00000 Completed Startup
2. Seed Round 21-Sep-2017 00.000 00.00 00.000 Completed Startup
1. Seed Round 30-Aug-2016 $750K $750K 00.000 Completed Startup
To view Tilos Therapeutics’s complete valuation and funding history, request access »

Tilos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00 00 00 00 00 00.000
To view Tilos Therapeutics’s complete cap table history, request access »

Tilos Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibody therapeutics designed to treat cancer, fibrosis and related disorders. The company's antibody ther
Biotechnology
Lexington, MA
00.00
00000 0000-00-00
000000&0 00.00

00000

n voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint oc
0000000000000
New York, NY
00 As of 0000
0000
00000 0000-00-00
00000000000 0000

000000

ore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation u
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tilos Therapeutics Competitors (127)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xalud Therapeutics Venture Capital-Backed New York, NY 00 0000 00000000000 0000
Intellia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
Arcutis Biotherapeutics Formerly VC-backed Westlake Village, CA 000 00.000 00000000 00.000
AnTolRx Venture Capital-Backed Cambridge, MA 000 00000000000 000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 127 competitors. Get the full list »

Tilos Therapeutics Patents

Tilos Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200140530-A1 Anti-lap antibody variants and uses thereof Active 10-Oct-2018 000000000
US-11130802-B2 Anti-lap antibody variants Active 10-Oct-2018 000000000 000
US-20220017612-A1 Anti-lap antibody variants and uses thereof Pending 10-Oct-2018 000000000
US-11230601-B2 Methods of using anti-lap antibodies Active 10-Oct-2017 00000000000 000
US-20190144549-A1 Anti-lap antibodies and uses thereof Active 10-Oct-2017 C07K16/2863 0
To view Tilos Therapeutics’s complete patent history, request access »

Tilos Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
Mass General Brigham Ventures Venture Capital Minority 000 0000 000000 0
ShangPharma Innovation Venture Capital Minority 000 0000 000000 0
To view Tilos Therapeutics’s complete investors history, request access »

Tilos Therapeutics FAQs

  • When was Tilos Therapeutics founded?

    Tilos Therapeutics was founded in 2016.

  • Who is the founder of Tilos Therapeutics?

    Barbara Fox Ph.D is the founder of Tilos Therapeutics.

  • Where is Tilos Therapeutics headquartered?

    Tilos Therapeutics is headquartered in Lexington, MA.

  • What industry is Tilos Therapeutics in?

    Tilos Therapeutics’s primary industry is Biotechnology.

  • Is Tilos Therapeutics a private or public company?

    Tilos Therapeutics is a Private company.

  • What is the current valuation of Tilos Therapeutics?

    The current valuation of Tilos Therapeutics is 00000.

  • What is Tilos Therapeutics’s current revenue?

    The current revenue for Tilos Therapeutics is 000000.

  • How much funding has Tilos Therapeutics raised over time?

    Tilos Therapeutics has raised $3.8M.

  • Who are Tilos Therapeutics’s investors?

    Boehringer Ingelheim Venture Fund, Mass General Brigham Ventures, and ShangPharma Innovation have invested in Tilos Therapeutics.

  • Who are Tilos Therapeutics’s competitors?

    Xalud Therapeutics, Intellia Therapeutics, Arcutis Biotherapeutics, AnTolRx, and NexImmune are some of the 127 competitors of Tilos Therapeutics.

  • When was Tilos Therapeutics acquired?

    Tilos Therapeutics was acquired on 01-Jun-2019.

  • Who acquired Tilos Therapeutics?

    Tilos Therapeutics was acquired by Merck & Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »